Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bio-Rad Laboratories Inc Reaffirms FY 2013 Revenue Guidance-Conference Call


Tuesday, 6 Aug 2013 05:00pm EDT 

Bio-Rad Laboratories Inc announced that for fiscal 2013, it remain cautiously optimistic of achieving the currency-neutral sales growth guidance of 3% to 3.5% for the base business it provided last February as well as expectation of a 3.5% to 4% topline growth when including the Serotec sales. The Company reported revenue of $2.069 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.149 billion for fiscal 2013. 

Company Quote

114.26
0.86 +0.76%
4:00pm EDT